MDMA-assisted psychotherapy
MDMA-assisted psychotherapy is a form of psychotherapy that involves the use of the drug 3,4-Methylenedioxymethamphetamine (MDMA) to assist in the therapeutic process. This approach is currently being researched for its potential to treat a variety of mental health conditions, including post-traumatic stress disorder (PTSD), anxiety, and depression.
History[edit | edit source]
The use of MDMA in psychotherapy has its roots in the 1970s and 1980s, when therapists began using the drug as a tool to facilitate empathy and introspection. However, the drug was classified as a Schedule I substance in 1985, which greatly limited its use in therapeutic settings.
Mechanism of Action[edit | edit source]
MDMA is a serotonin-releasing agent that increases the release of serotonin in the brain. This can lead to feelings of euphoria, increased empathy, and heightened introspection, which can be beneficial in a therapeutic setting. The drug also has effects on the norepinephrine and dopamine systems, which can lead to increased energy and focus.
Therapeutic Use[edit | edit source]
In MDMA-assisted psychotherapy, the drug is administered in a controlled setting under the supervision of a trained therapist. The patient is then guided through a series of therapeutic exercises designed to help them explore and process difficult emotions and experiences.
Research and Efficacy[edit | edit source]
Several studies have shown promising results for the use of MDMA-assisted psychotherapy in treating PTSD. A 2021 study published in Nature Medicine found that patients who received MDMA-assisted psychotherapy showed significantly greater reductions in PTSD symptoms compared to those who received placebo.
Risks and Side Effects[edit | edit source]
Like all drugs, MDMA carries risks and potential side effects. These can include nausea, anxiety, insomnia, and dehydration. There is also the risk of serotonin syndrome, a potentially life-threatening condition that can occur when there is too much serotonin in the brain.
Legal Status[edit | edit source]
As of 2021, MDMA is classified as a Schedule I substance in the United States, meaning it is illegal to manufacture, distribute, or possess. However, the Food and Drug Administration (FDA) has granted "breakthrough therapy" designation to MDMA-assisted psychotherapy for PTSD, which could potentially expedite its approval for medical use.
See Also[edit | edit source]
MDMA-assisted psychotherapy Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD